Gibson Dunn has advised Avere Therapeutics. Cooley has advised the placement agents. Avere Therapeutics, Inc. (“Avere”), a privately-held biotechnology company, has announced a $500 million private…
Avere Therapeutics Secures $500 Million in Private Placement for Development of Once-Weekly Oral IL-23 Therapy
